JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Home・Elenco Azioni・Roivant Sciences Ltd

Roivant Sciences Ltd

Chiusa

SettoreSettore sanitario

27.83 -2.66

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

27.83

Massimo

28.12

Metriche Chiave
By Trading Economics
Entrata	-200M -314M
Vendite	428K 2M
Margine di Profitto	-15,692.896
Dipendenti	750
EBITDA	-132M -290M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+24.69% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	5B 20B
Apertura precedente	30.49
Chiusura precedente	27.83

Notizie sul Sentiment di mercato

By Acuity

67%

33%

310 / 347 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

11 / 11.18 Supporto e resistenza

Roivant Sciences Ltd Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

5 mag 2026, 23:43 UTC

Principali Notizie su Eventi

New Zealand's Unemployment Rate Falls in 1Q

5 mag 2026, 23:20 UTC

Azioni calde

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5 mag 2026, 21:48 UTC

Utili

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5 mag 2026, 21:05 UTC

Acquisizioni, Fusioni, Takeovers

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6 mag 2026, 00:00 UTC

Discorsi di Mercato

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5 mag 2026, 23:39 UTC

Discorsi di Mercato

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5 mag 2026, 22:26 UTC

Discorsi di Mercato

AMD Data-Center Business Continues to Surge -- Market Talk

5 mag 2026, 22:20 UTC

Discorsi di Mercato

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5 mag 2026, 22:08 UTC

Utili

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5 mag 2026, 22:07 UTC

Utili

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mag 2026, 21:48 UTC

Utili

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5 mag 2026, 21:48 UTC

Utili

Pan American Silver 1Q Rev $1.2B >PAAS

5 mag 2026, 21:42 UTC

Utili

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mag 2026, 21:38 UTC

Utili

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mag 2026, 21:30 UTC

Utili

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mag 2026, 21:29 UTC

Utili

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mag 2026, 21:26 UTC

Utili

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5 mag 2026, 21:25 UTC

Utili

Alcon Inc. 1Q EPS 39c >ALC.EB

5 mag 2026, 21:25 UTC

Utili

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5 mag 2026, 21:24 UTC

Utili

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mag 2026, 21:18 UTC

Utili

Mistras Backs 2026 Rev $730M-$750M >MG

5 mag 2026, 21:17 UTC

Utili

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5 mag 2026, 21:15 UTC

Utili

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5 mag 2026, 21:12 UTC

Utili

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5 mag 2026, 21:11 UTC

Utili

SSR Mining 1Q Rev $581.8M >SSRM

5 mag 2026, 21:10 UTC

Utili

SSR Mining 1Q Adj EPS $1.15 >SSRM

5 mag 2026, 21:10 UTC

Utili

SSR Mining 1Q EPS $1.16 >SSRM

5 mag 2026, 21:08 UTC

Utili

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mag 2026, 21:01 UTC

Utili

Intact Financial 1Q EPS C$4.12 >IFC.T

5 mag 2026, 21:01 UTC

Azioni calde

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Confronto tra pari

Modifica del prezzo

Roivant Sciences Ltd Previsione

Obiettivo di Prezzo

By TipRanks

24.69% in crescita

Previsioni per 12 mesi

Media 34.7 USD 24.69%

Alto 41 USD

Basso 29 USD

Basato su 10 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Roivant Sciences Ltd - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

10 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 10 che hanno fornito valutazioni azionarie a Roivant Sciences Ltd - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

11 / 11.18Supporto e resistenza

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentiment

By Acuity

310 / 347 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.